Authors: Shane A. Landry, Siobhan Banks, Peter A. Cistulli, Garun S. Hamilton, Laure Héraud, Kristina Kairaitis, Steven Lubke, Sutapa Mukherjee, Teanau Roebuck, Joesph Soda, Darren Umbers, Shantha M. W. Rajaratnam, Darren Mansfield
Background and objective
Obstructive sleep apnoea (OSA) is a prevalent sleep disorder associated with increased cardiovascular morbidity and mortality. Whether treatment of OSA improves cardiovascular risk remains controversial. Our aim was to determine a consensus opinion of key sleep medicine stakeholder groups as to the cardiovascular benefits of treating moderate–severe OSA.